Dosing of insulin glargine in the treatment of type 2 diabetes

Clinical Therapeutics

Volumn 29, Issue 6, 2007, Pages 987-999

  Barnett, Anthony ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

dosing; insulin glargine; type 2 diabetes

Indexed keywords

BIPHASIC INSULIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ALGORITHM; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PEER REVIEW; RANDOMIZATION; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; WEIGHT GAIN;

ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS;

EID: 34547601276     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.06.018     Document Type: Review

References (47)

1. [published correction appears in Diabetes. 1996;45:1655]. The UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 44 (1995) 1249-1258
2. Gerich J. Physiology of glucose homeostasis. Diabetes Obes Metab 2 (2000) 345-350
3. The European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med 16 (1999) 716-730
4. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl 1 (2007) S4-S41
5. Nathan D., Buse J., Davidson M., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [published correction appears in Diabetes Care. 2006;49:2816-2818]. Diabetes Care 29 (2006) 1963-1972
6. Pearson J., and Powers M. Systematically initiating insulin: The staged diabetes management approach. Diabetes Educ 32 Suppl 1 (2006) 19S-28S
7. for the VADT Study Group. Kirkman M., McCarren M., Shah J., et al. The association between metabolic control and prevalent macrovascular disease in type 2 diabetes: The VA Cooperative Study in diabetes. Diabetes Complications 20 (2006) 75-80
8. Spijkerman A., Henry R., Dekker J., et al. Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screening and patients newly diagnosed in general practice: The Hoorn Screening Study. J Intern Med 256 (2004) 429-436
9. Selvin E., Marinopoulos S., Berkenblit G., et al. Glycosylated hemoglobin and cardiovascular diseasein diabetes mellitus. Ann Intern Med 141 (2004) 421-431
10. Abdul-Ghani M., Nawaf G., Nawaf F., et al. Increased prevalence of microvascular complications in type 2 diabetes patients with the metabolic syndrome. Isr Med Assoc J 8 (2006) 378-382
11. O'Brien J., Patrick A., and Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 25 (2003) 1017-1038
12. Nazimek-Siewniak B., Moczulski D., and Grzeszczak W. Risk of macrovascular and microvascular complications in type 2 diabetes: Results of longitudinal study design. J Diabetes Complications 16 (2002) 271-276
13. Stratton I., Adler A., Neil H., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
14. Genuth S., Eastman R., Kahn R., et al. Implications of the United Kingdom prospective diabetes study. Diabetes Care 26 Suppl 1 (2003) S28-S32
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet 352 (1998) 837-853
16. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1558]. Lancet 352 (1998) 854-865
17. McCrimmon R., and Frier B. Hypoglycaemia, the most feared complication of insulin therapy. Diabet Metab 20 (1994) 503-512
18. Cryer P. Hypoglycemia is the limiting factor in the management of diabetes. Diabete Metab Res Rev 15 (1999) 42-46
19. Sigal R., Kenny G., Wasserman D., et al. Physical activity/exercise and type 2 diabetes: A consensus statement from the American Diabetes Association. Diabetes Care 29 (2006) 1433-1438
20. Eurich D., Majumdar S., McAlister F., et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28 (2005) 2345-2351
21. Johnson J., Majumdar S., Simpson S., and Toth E. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25 (2002) 2244-2248
22. Johnson J., Simpson S., Toth E., and Majumdar S. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 22 (2005) 497-502
23. Koski R. Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus. Diabetes Educ 32 (2006) 869-876
24. for the UK Prospective Diabetes Study Group. Wright A., Burden A., Paisey R., et al. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57) [published correction appears in Diabetes Care. 2002;25:1268]. Diabetes Care 25 (2002) 330-336
25. Lepore M., Pampanelli S., Fanelli C., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000) 2142-2148
26. Heinemann L., Linkeschova R., Rave K., et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23 (2000) 644-649
27. for the HOE 901/3005 Study Group. Yki-Jarvinen H., Dressler A., and Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23 (2000) 1130-1136
28. Brown J., Nichols G., and Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 27 (2004) 1535-1540
29. Fox K., Gerber R., Bolinde B., et al. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002. Clin Ther 28 (2006) 388-395
30. for the DARTS/MEMO Collaboration. Leese G., Wang J., Broomhall J., et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use. Diabetes Care 26 (2003) 1176-1180
31. Owens D., Coates P., Luzio S., et al. Pharmacokinetics of 1251-labeled insulin glargine (HOE901) in healthy men: Comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 23 (2000) 813-819
32. Massi Benedetti M., Humburg E., Dressler A., and Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 35 (2003) 189-196
33. Rosenstock J., Schwartz S., Clark Jr. C., et al. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24 (2001) 631-636
34. for the Insulin Glargine 4002 Study Investigators. Riddle M., Rosenstock J., and Gerich J. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
35. Riddle M. Timely initiation of basal insulin. Am J Med 116 Suppl 3A (2004) 3S-9S
36. Rosenstock J. Insulin therapy: Optimizing control in type 1 and type 2 diabetes. Clin Cornerstone 4 (2001) 50-64
37. Rosenstock J., Dailey G., Massi-Benedetti M., et al. Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28 (2005) 950-955
38. Yki-Jarvinen H., Kauppinen-Makelin R., Tiikkainen M., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia 49 (2006) 442-451
39. for the ATLANTUS Study Group. Davies M., Storms F., Shuder S., et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care 28 (2005) 1282-1288
40. Janka H., Plewe G., Riddle M., et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28 (2005) 254-259
41. for the INITIATE Study Group. Raskin P., Allen E., Hollander P., et al. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265
42. for the Canadian INSIGHT Study Group. Gerstein H., Yale J., Harris S., et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 23 (2006) 736-742
43. for the 4001 Study Group. Fritsche A., Schweitzer M., and Haring H. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138 (2003) 952-959
44. for the LEAD Study Investigators Group. Pan C., Sinnassamy P., Chung K., and Kim K. Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Res Clin Pract 76 (2007) 111-118
45. Monnier L., and Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: Indications and modalities. Diabetes Metab 32 (2006) 7-13
46. Riddle M. Making the transition from oral to insulin therapy. Am J Med 118 Suppl 5A (2005) 14S-20S
47. Yki-Jarvinen H. Insulin therapy in type 2 diabetes: Role of the long-acting insulin glargine analogue. Eur J Clin Invest 34 (2004) 410-416